Amgen will acquire Rodeo Therapeutics, along with its preclinical program focused on the development of potential therapies for inflammatory and fibrotic diseases like pulmonary fibrosis (PF). “With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and…
News
Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients. Ofev appears to…
Tyvaso (inhaled treprostinil) has been approved as the first treatment to improve exercise ability in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the U.S. PH-ILD is an umbrella term that encompasses idiopathic pulmonary fibrosis (IPF) and other lung fibrotic-related conditions. “The regulatory approval of…
A protein linked to lung inflammation, known as Krebs von den Lungen-6, or KL-6, was found to be a reliable biomarker for the prognosis of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer, predicting IPF progression and indicating an individual’s response to treatment, an analysis shows. The results…
As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking. But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…
The ability of Ofev (nintedanib) to improve lung function in people with progressive fibrosing interstitial lung diseases (ILDs) is not influenced by their use of immunomodulatory therapies, a study indicates. The study, “Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases,” was published in the journal…
Changes for the better in diagnosing idiopathic pulmonary fibrosis (IPF) and managing patients in the U.K. are evident in recent years, a real-world study based on registry data indicates. “Patient registries offer a unique opportunity to collect longitudinal data on uncommon diseases, such as IPF,” the researchers…
Lassen Therapeutics and researchers at Cedars Sinai Medical Center in California will together investigate the role of the immune signaling protein interleukin-11 (IL-11) in idiopathic pulmonary fibrosis (IPF), and its potential as a…
Exposure to fine particulate air pollutants, such as PM2.5 and nitric oxide (NO), raises the risk for acute flare-ups of idiopathic pulmonary fibrosis (IPF) within a time window of one to two months, according to data from a recent study. The study, “Exposure to PM2.5 is…
VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung diseases. Using artificial intelligence, PulmoSIM’s goal is to assess which therapies previously approved by the U.S. Food and Drug Administration for certain conditions can be effective for the treatment of…
